USL-311

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameUSL-311
Drug Alias NameUSL-311
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-X-C motif chemokine receptor 4 antagonists
TargetsC-X-C motif chemokine receptor 4
Therapy Area/IndicationsSolid tumoursAnti-Glomerular Basement Membrane Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpain
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLigand Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProximagen Llc
Active IndicationsN/A
Inactive IndicationsSolid tumoursAnti-Glomerular Basement Membrane Disease

Other Information

ATC CodeN/A
Related LinksN/A